Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04414163 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04414163 · ClinicalTrials.gov record · last posted 2026-04-24

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

StatusActive, Not Recruiting
PhasePhase 2
Started2020-10-27
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type

Amendment record 7 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 7 times since 2020-05-29; most recent amendment 2026-04-21. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-04-10
Status change Recruiting→Active, Not Recruitingv4
2020-10-23
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT04414163
Lead Sponsor ImmuneOncia Therapeutics Inc.
Conditions Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma
Enrollment 23 participants
Start Date 2020-10-27
Primary Completion 2024-07-23 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-04-24